Pub Date : 2024-12-01Epub Date: 2024-11-22DOI: 10.1080/20565623.2024.2432233
Noor A A Giesbertz, Lars S Assen, Wim H van Harten, Annelien L Bredenoord
Introduction: Particularly in genetics, former results can gain new meaning in the course of time. This raises questions about when professionals should recontact patients with new information. The aim of this focus group study is to clarify how different stakeholders in oncology think about the extent and limits of a duty to recontact.
Materials and methods: One focus group with oncology patients (n = 12) and two groups with healthcare professionals (total n = 13) were conducted. In general, there was support for recontacting patients. The scope and extent of this duty was, however, perceived differently. Differences and similarities on the following six contextual factors are discussed: information features, costs and efforts, personal preferences, who is contacted, clinic or research setting, and time.
Discussion: Oncology patients were clear in their wish to receive updates while the professionals were more hesitant to consider recontact as a standard of care. This is not surprising as recontacting patients with new information would mean a shift from a patient-initiated approach toward an information-initiated approach. This entails a different way of offering healthcare. Furthermore, the question is not only what professionals' responsibilities are, but how to design a system that complies with patients' wishes to receive updates.
{"title":"DNA sequencing in oncology: a focus group study on a duty to recontact.","authors":"Noor A A Giesbertz, Lars S Assen, Wim H van Harten, Annelien L Bredenoord","doi":"10.1080/20565623.2024.2432233","DOIUrl":"10.1080/20565623.2024.2432233","url":null,"abstract":"<p><strong>Introduction: </strong>Particularly in genetics, former results can gain new meaning in the course of time. This raises questions about when professionals should recontact patients with new information. The aim of this focus group study is to clarify how different stakeholders in oncology think about the extent and limits of a duty to recontact.</p><p><strong>Materials and methods: </strong>One focus group with oncology patients (n = 12) and two groups with healthcare professionals (total n = 13) were conducted. In general, there was support for recontacting patients. The scope and extent of this duty was, however, perceived differently. Differences and similarities on the following six contextual factors are discussed: information features, costs and efforts, personal preferences, who is contacted, clinic or research setting, and time.</p><p><strong>Discussion: </strong>Oncology patients were clear in their wish to receive updates while the professionals were more hesitant to consider recontact as a standard of care. This is not surprising as recontacting patients with new information would mean a shift from a <i>patient-initiated</i> approach toward an <i>information-initiated</i> approach. This entails a different way of offering healthcare. Furthermore, the question is not only what professionals' responsibilities are, but how to design a system that complies with patients' wishes to receive updates.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2432233"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-11-19DOI: 10.1080/20565623.2024.2430417
R Ben Salah, M Boudaya, S Fendri, R Marrekchi, Z Bahloul, K Jamoussi
Aims: The objectives of this study were to determine the plasma homocysteine (Hcy) levels and the prevalence of Hyperhomocysteinemia (HHC) in a group of Tunisian patients with deep vein thrombosis (DVT) by comparing it with healthy controls.
Methods: it was an observational case-control study including patients hospitalized for the management of unprovoked DVT. For each subject, a routine biochemical assay was conducted, including plasma homocysteine measurement and determination of vitamin B12 and B9 levels, as these vitamins are essential for assessing hyperhomocysteinemia in DVT patients due to their role in regulating homocysteine.
Results: We observed an increased mean plasma Hcy level compared to controls and the prevalence of Hyperhomocysteinemia 61.7% against 4% in the control subjects. The risk of developing DVT with HHC is 3.54.
Conclusion: Our study found that homocysteine levels were higher in patients with DVT than in controls.
{"title":"Hyperhomocysteinemia prevalence among patients with venous thromboembolism.","authors":"R Ben Salah, M Boudaya, S Fendri, R Marrekchi, Z Bahloul, K Jamoussi","doi":"10.1080/20565623.2024.2430417","DOIUrl":"10.1080/20565623.2024.2430417","url":null,"abstract":"<p><strong>Aims: </strong>The objectives of this study were to determine the plasma homocysteine (Hcy) levels and the prevalence of Hyperhomocysteinemia <b>(</b>HHC) in a group of Tunisian patients with deep vein thrombosis (DVT) by comparing it with healthy controls.</p><p><strong>Methods: </strong>it was an observational case-control study including patients hospitalized for the management of unprovoked DVT. For each subject, a routine biochemical assay was conducted, including plasma homocysteine measurement and determination of vitamin B12 and B9 levels, as these vitamins are essential for assessing hyperhomocysteinemia in DVT patients due to their role in regulating homocysteine.</p><p><strong>Results: </strong>We observed an increased mean plasma Hcy level compared to controls and the prevalence of Hyperhomocysteinemia 61.7% against 4% in the control subjects. The risk of developing DVT with HHC is 3.54.</p><p><strong>Conclusion: </strong>Our study found that homocysteine levels were higher in patients with DVT than in controls.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2430417"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-11-22DOI: 10.1080/20565623.2024.2430357
M Thirumal, S Monika
{"title":"Transforming Healthcare: The power and potential of digital medicine.","authors":"M Thirumal, S Monika","doi":"10.1080/20565623.2024.2430357","DOIUrl":"10.1080/20565623.2024.2430357","url":null,"abstract":"","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2430357"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-11-22DOI: 10.1080/20565623.2024.2432180
Martha Fors, Santiago J Ballaz
<p><strong>Aims/background: </strong>We looked at novel hematological composites like the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, red cell distribution width-to-lymphocyte ratio, red cell distribution width-to-platelet ratio, leukocyte-to-C reactive protein ratio, and lymphocyte-to-C reactive protein ratio as explanatory variables for COVID-19 patients´ hospital length of stay (LoS).</p><p><strong>Methods: </strong>The association of hematological indices with LoS was analyzed on 2930 COVID-19 patients using the univariate and multivariable Cox proportional hazards regression models with enter method. The Kaplan-Meier survival estimates were applied to LoS.</p><p><strong>Results: </strong>The survivors´ mean LoS was 7.8 ± 24.0 days, but the deaths´ mean LoS was 38.6 ± 41.9 days (W = 31338, p < 0.01). Every hematological scores representative of the inflammatory status was significantly correlated in the univariate analysis with a prolonged LoS (p < 0.001). In the multivariate analysis, it was discovered that just the monocyte-to-lymphocyte and lymphocyte-to-C reactive protein ratios had not achieved statistical significance. However, most systemic inflammation measures showed hazards ratios close to one. One exemption was the red cell distribution width-to-platelet ratio (RPR) index, which can increase the probability of a longer hospital stay by up to ten times (HR(IC95%) = 0.092(0.03-0.29); p < 0.001).</p><p><strong>Conclusion: </strong>The most effective biomarker to identify COVID-19 patients at high risk for extended hospital stay was RPR.</p><p><strong>Highlights: </strong><b>Introduction</b>Determining hospital Length of Stay (LoS) is vital for resource management, especially for future COVID-19 outbreaks.Previous studies have primarily focused on sociodemographic and clinical attributes, along with resource availability, but have not accounted for other factors like routine laboratory tests, which can significantly impact LoS predictions.This study examines novel hematology scores as predictors of LoS, emphasizing their importance in resource-limited settings like Ecuador.<b>Methods</b>This retrospective cohort study analyzed 2,930 COVID-19 patients admitted to Hospital IESS Quito Sur in Ecuador focusing on confirmed cases with complete blood count (CBC) values to assess LoS.The study explored various hematological ratios, such as the neutrophil-to-lymphocyte ratio (NLR) and red cell distribution width-to-lymphocyte ratio (RLR), as potential predictors of LoS and in-hospital outcomes for COVID-19 patients, using a combination of univariate and multivariable Cox proportional hazards regression models.Kaplan-Meier survival estimates and log-rank tests were used to analyze survival and discharge probabilities over time, highlighting sex-dependent effects and the significant association between selected hematological indices and patient outcomes.<b>Results</b>The mean LoS for survivors was s
{"title":"Red cell distribution width-to-platelet ratio (RPR) as a predictor of prolonged stay at hospital for COVID-19 inpatients.","authors":"Martha Fors, Santiago J Ballaz","doi":"10.1080/20565623.2024.2432180","DOIUrl":"10.1080/20565623.2024.2432180","url":null,"abstract":"<p><strong>Aims/background: </strong>We looked at novel hematological composites like the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, red cell distribution width-to-lymphocyte ratio, red cell distribution width-to-platelet ratio, leukocyte-to-C reactive protein ratio, and lymphocyte-to-C reactive protein ratio as explanatory variables for COVID-19 patients´ hospital length of stay (LoS).</p><p><strong>Methods: </strong>The association of hematological indices with LoS was analyzed on 2930 COVID-19 patients using the univariate and multivariable Cox proportional hazards regression models with enter method. The Kaplan-Meier survival estimates were applied to LoS.</p><p><strong>Results: </strong>The survivors´ mean LoS was 7.8 ± 24.0 days, but the deaths´ mean LoS was 38.6 ± 41.9 days (W = 31338, p < 0.01). Every hematological scores representative of the inflammatory status was significantly correlated in the univariate analysis with a prolonged LoS (p < 0.001). In the multivariate analysis, it was discovered that just the monocyte-to-lymphocyte and lymphocyte-to-C reactive protein ratios had not achieved statistical significance. However, most systemic inflammation measures showed hazards ratios close to one. One exemption was the red cell distribution width-to-platelet ratio (RPR) index, which can increase the probability of a longer hospital stay by up to ten times (HR(IC95%) = 0.092(0.03-0.29); p < 0.001).</p><p><strong>Conclusion: </strong>The most effective biomarker to identify COVID-19 patients at high risk for extended hospital stay was RPR.</p><p><strong>Highlights: </strong><b>Introduction</b>Determining hospital Length of Stay (LoS) is vital for resource management, especially for future COVID-19 outbreaks.Previous studies have primarily focused on sociodemographic and clinical attributes, along with resource availability, but have not accounted for other factors like routine laboratory tests, which can significantly impact LoS predictions.This study examines novel hematology scores as predictors of LoS, emphasizing their importance in resource-limited settings like Ecuador.<b>Methods</b>This retrospective cohort study analyzed 2,930 COVID-19 patients admitted to Hospital IESS Quito Sur in Ecuador focusing on confirmed cases with complete blood count (CBC) values to assess LoS.The study explored various hematological ratios, such as the neutrophil-to-lymphocyte ratio (NLR) and red cell distribution width-to-lymphocyte ratio (RLR), as potential predictors of LoS and in-hospital outcomes for COVID-19 patients, using a combination of univariate and multivariable Cox proportional hazards regression models.Kaplan-Meier survival estimates and log-rank tests were used to analyze survival and discharge probabilities over time, highlighting sex-dependent effects and the significant association between selected hematological indices and patient outcomes.<b>Results</b>The mean LoS for survivors was s","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2432180"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-11-22DOI: 10.1080/20565623.2024.2428077
M Angeles Vaz-Salgado, Victor Albarran, Javier Pozas, Reyes Ferreiro, Vanessa Pachón, Federico Longo, Mercedes Rodriguez, Emma Barreto, Julie Earl
Background: Single-nucleotide polymorphisms (SNPs) in enzyme-coding genes play a role in susceptibility to anti-cancer therapy.
Materials & methods: A prospective study was performed of the relationship between enzyme activity and treatment response, drug toxicity and hypersensitivity reactions in 51 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. SNP analysis was performed in 22 enzyme-coding genes with a previously described role in treatment efficacy.
Results: SLC6 and MTHR enzyme activity was related with rates of progressive disease, GSTP1 activity with anti-EGFR antibodies-related skin toxicity, CYP3A5 and MTHR with chemotherapy dose reduction, CYP2B6, IL10, MTHR and TYMS activity with the risk of drug hypersensitivity reactions.
Conclusion: Pharmacogenetics is a valuable predictive marker in oncology, related to chemotherapy treatment response, toxicity and hypersensitivity.
背景:酶编码基因中的单核苷酸多态性(SNPs)在抗癌治疗的易感性中发挥作用:对51名接受氟嘧啶类化疗的结直肠癌患者的酶活性与治疗反应、药物毒性和超敏反应之间的关系进行了前瞻性研究。研究对 22 个酶编码基因中的 SNP 进行了分析,这些基因以前曾被描述过在疗效中的作用:结果:SLC6和MTHR酶活性与疾病进展率有关,GSTP1活性与抗EGFR抗体相关的皮肤毒性有关,CYP3A5和MTHR与化疗剂量减少有关,CYP2B6、IL10、MTHR和TYMS活性与药物超敏反应风险有关:药物遗传学是肿瘤学中与化疗反应、毒性和超敏反应相关的重要预测指标。
{"title":"Single nucleotide polymorphisms: impact on susceptibility to chemotherapy in patients with colorectal cancer.","authors":"M Angeles Vaz-Salgado, Victor Albarran, Javier Pozas, Reyes Ferreiro, Vanessa Pachón, Federico Longo, Mercedes Rodriguez, Emma Barreto, Julie Earl","doi":"10.1080/20565623.2024.2428077","DOIUrl":"10.1080/20565623.2024.2428077","url":null,"abstract":"<p><strong>Background: </strong>Single-nucleotide polymorphisms (SNPs) in enzyme-coding genes play a role in susceptibility to anti-cancer therapy.</p><p><strong>Materials & methods: </strong>A prospective study was performed of the relationship between enzyme activity and treatment response, drug toxicity and hypersensitivity reactions in 51 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. SNP analysis was performed in 22 enzyme-coding genes with a previously described role in treatment efficacy.</p><p><strong>Results: </strong>SLC6 and MTHR enzyme activity was related with rates of progressive disease, GSTP1 activity with anti-EGFR antibodies-related skin toxicity, CYP3A5 and MTHR with chemotherapy dose reduction, CYP2B6, IL10, MTHR and TYMS activity with the risk of drug hypersensitivity reactions.</p><p><strong>Conclusion: </strong>Pharmacogenetics is a valuable predictive marker in oncology, related to chemotherapy treatment response, toxicity and hypersensitivity.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2428077"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-11-19DOI: 10.1080/20565623.2024.2428119
Rapuru Rushendran, Vellapandian Chitra
Introduction: Chronic migraine is recognized by the WHO as one of the most debilitating chronic conditions. It is primarily caused by central sensitization of the trigeminal nucleus caudalis. Key biomarkers associated with migraine include NFkB, IL-1β, CGRP, and iNOS. While CGRP antagonists have proven effective in treating migraines, Chrysanthemum indicum L., a traditional herbal remedy, has not been established as a treatment.
Methods: To address this, we investigated whether Fargesin, a lignan found in CI, could potentially reduce migraines by targeting these biomarkers. We conducted pharmacokinetic, toxicological, and in-silico studies. Molecular docking studies revealed a strong interaction between Fargesin and CGRP/iNOS.
Results: The pharmacokinetic analysis indicated robust intestinal absorption and effective penetration of the blood-brain barrier. In-silico toxicity assessments showed favorable results. Promising interactions with drug targets were observed in bioactivity tests.
Conclusion: Fargesin from Chrysanthemum indicum may hold potential as a therapeutic agent for migraines.
{"title":"Exploring the potential of Fargesin from <i>Chrysanthemum indicum</i> for chronic migraine: <i>in-silico</i> and pharmacokinetic study.","authors":"Rapuru Rushendran, Vellapandian Chitra","doi":"10.1080/20565623.2024.2428119","DOIUrl":"10.1080/20565623.2024.2428119","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic migraine is recognized by the WHO as one of the most debilitating chronic conditions. It is primarily caused by central sensitization of the trigeminal nucleus caudalis. Key biomarkers associated with migraine include NFkB, IL-1β, CGRP, and iNOS. While CGRP antagonists have proven effective in treating migraines, Chrysanthemum indicum L., a traditional herbal remedy, has not been established as a treatment.</p><p><strong>Methods: </strong>To address this, we investigated whether Fargesin, a lignan found in CI, could potentially reduce migraines by targeting these biomarkers. We conducted pharmacokinetic, toxicological, and in-silico studies. Molecular docking studies revealed a strong interaction between Fargesin and CGRP/iNOS.</p><p><strong>Results: </strong>The pharmacokinetic analysis indicated robust intestinal absorption and effective penetration of the blood-brain barrier. In-silico toxicity assessments showed favorable results. Promising interactions with drug targets were observed in bioactivity tests.</p><p><strong>Conclusion: </strong>Fargesin from Chrysanthemum indicum may hold potential as a therapeutic agent for migraines.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2428119"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: This study explored Panduratin A's protective effects against DSS-induced colitis in mice, focusing on reducing inflammation and oxidative stress in the colon.
Methods: Mice were treated with dextran sodium sulfate (DSS) and Panduratin A (3, 6, 18 mg/kg), and changes in body weight, colon length, Disease Activity Index (DAI), histopathology, inflammation markers including tumor necrosis factor- α (TNF-α), Interleukin-1 β (IL-1β), Myeloperoxidase (MPO), and oxidative stress, Malondialdehyde (MDA) were evaluated.
Results: Panduratin A significantly reversed DSS-induced symptoms, including body weight loss, colonic length shortening, and DAI increase, while reducing histopathological damage. It lowered inflammatory markers and oxidative stress, suppressed NF-κB activation, and enhanced Nrf2 and HO-1 expression.
Conclusion: Panduratin A shows promise as a colitis treatment, warranting further research for broader clinical application.
目的:本研究探讨了 Panduratin A 对右旋糖酐硫酸钠诱导的小鼠结肠炎的保护作用,重点是减少结肠中的炎症和氧化应激:用葡聚糖硫酸钠(DSS)和 Panduratin A(3、6、18 毫克/千克)治疗小鼠,评估小鼠体重、结肠长度、疾病活动指数(DAI)、组织病理学、肿瘤坏死因子-α(TNF-α)、白细胞介素-1 β(IL-1β)、髓过氧化物酶(MPO)等炎症标志物和丙二醛(MDA)等氧化应激的变化:结果:Panduratin A能明显逆转DSS诱导的症状,包括体重减轻、结肠长度缩短和DAI增加,同时减轻组织病理学损伤。它降低了炎症指标和氧化应激,抑制了NF-κB的激活,并增强了Nrf2和HO-1的表达:结论:Panduratin A有望作为结肠炎的治疗药物,值得进一步研究以扩大临床应用。
{"title":"Panduratin A mitigates inflammation and oxidative stress in DSS-induced colitis mice model.","authors":"Abdelrahim Alqudah, Esam Qnais, Omar Gammoh, Yousra Bseiso, Mohammed Wedyan, Muna Oqal","doi":"10.1080/20565623.2024.2428129","DOIUrl":"10.1080/20565623.2024.2428129","url":null,"abstract":"<p><strong>Aim: </strong>This study explored Panduratin A's protective effects against DSS-induced colitis in mice, focusing on reducing inflammation and oxidative stress in the colon.</p><p><strong>Methods: </strong>Mice were treated with dextran sodium sulfate (DSS) and Panduratin A (3, 6, 18 mg/kg), and changes in body weight, colon length, Disease Activity Index (DAI), histopathology, inflammation markers including tumor necrosis factor- α (TNF-α), Interleukin-1 β (IL-1β), Myeloperoxidase (MPO), and oxidative stress, Malondialdehyde (MDA) were evaluated.</p><p><strong>Results: </strong>Panduratin A significantly reversed DSS-induced symptoms, including body weight loss, colonic length shortening, and DAI increase, while reducing histopathological damage. It lowered inflammatory markers and oxidative stress, suppressed NF-κB activation, and enhanced Nrf2 and HO-1 expression.</p><p><strong>Conclusion: </strong>Panduratin A shows promise as a colitis treatment, warranting further research for broader clinical application.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2428129"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01Epub Date: 2024-11-25DOI: 10.1080/20565623.2024.2430902
Emad Hijazi
Background: Coronary artery bypass graft (CABG) surgery brings significant cardiac benefits but also risks post-operative complications, including cognitive impairments and infections.
Materials & methods: We analyzed 108 patient records between 2011 and 2021 at the Princess Muna Al-Hussein Cardiac Center, Irbid, Jordan. The primary endpoint was the occurrence of postoperative events.
Results: Few patients (8.3%) faced complications like stroke and infections, with age and ICU stay length as significant risk factors. Patients with complications often experienced left ventricular impairments and required inotropic support.
Conclusion: The study highlights the need for understanding CABG surgery complications to improve outcomes, emphasizing preventive care and personalized follow-up.
{"title":"Investigating outcomes of coronary artery bypass graft (CABG) surgery: a single-center retrospective study in Jordan.","authors":"Emad Hijazi","doi":"10.1080/20565623.2024.2430902","DOIUrl":"10.1080/20565623.2024.2430902","url":null,"abstract":"<p><strong>Background: </strong>Coronary artery bypass graft (CABG) surgery brings significant cardiac benefits but also risks post-operative complications, including cognitive impairments and infections.</p><p><strong>Materials & methods: </strong>We analyzed 108 patient records between 2011 and 2021 at the Princess Muna Al-Hussein Cardiac Center, Irbid, Jordan. The primary endpoint was the occurrence of postoperative events.</p><p><strong>Results: </strong>Few patients (8.3%) faced complications like stroke and infections, with age and ICU stay length as significant risk factors. Patients with complications often experienced left ventricular impairments and required inotropic support.</p><p><strong>Conclusion: </strong>The study highlights the need for understanding CABG surgery complications to improve outcomes, emphasizing preventive care and personalized follow-up.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2430902"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11591588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: This study aimed to explore using peripheral blood mononuclear cell (PBMC)-derived chimeric antigen receptor (CAR) NK cells targeting ROBO1 as a personalized medicine approach for ovarian cancer. Methods: A two-step strategy generated ROBO1-targeted CAR NK cells from PBMCs of ovarian cancer patients. Efficacy was evaluated using xCELLigence RTCA, CCK-8 and Live/Dead fluorescence assays. Results: ROBO1-NK cells exhibited higher efficiency in eradicating primary ovarian cancer cells and lysing ovarian tumor organoids compared with primary NK cells without ROBO1-CAR modification. Conclusion: These findings highlight the potential of developing ROBO1-targeted CAR-NK cells from patients' PBMCs as a personalized treatment option for ovarian cancer.
{"title":"Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids.","authors":"Yan Zhu, Luanhong Wang, Biyu Jiang, Yini Wang, Qing Wu, Sihua Hong, Xiaojing Wang, Yuancheng Li, Tian Guan, Haoyu Zeng, Congzhu Li","doi":"10.2144/fsoa-2023-0135","DOIUrl":"10.2144/fsoa-2023-0135","url":null,"abstract":"<p><p><b>Aim:</b> This study aimed to explore using peripheral blood mononuclear cell (PBMC)-derived chimeric antigen receptor (CAR) NK cells targeting ROBO1 as a personalized medicine approach for ovarian cancer. <b>Methods:</b> A two-step strategy generated ROBO1-targeted CAR NK cells from PBMCs of ovarian cancer patients. Efficacy was evaluated using xCELLigence RTCA, CCK-8 and Live/Dead fluorescence assays. <b>Results:</b> ROBO1-NK cells exhibited higher efficiency in eradicating primary ovarian cancer cells and lysing ovarian tumor organoids compared with primary NK cells without ROBO1-CAR modification. <b>Conclusion:</b> These findings highlight the potential of developing ROBO1-targeted CAR-NK cells from patients' PBMCs as a personalized treatment option for ovarian cancer.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2340186"},"PeriodicalIF":2.4,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-06eCollection Date: 2024-01-01DOI: 10.2144/fsoa-2023-0144
Humaira Jabbar, Tooba Noor, Muhammad A Obaid, Areej Shakil, Muhammad I Obaid, Syeda I Aaqil, Usama Aa Memon, Zoha Mohsin
Aim: Gastro-esophageal reflux disease (GERD) is a growing health concern. Methods: In this cross-sectional study, participants' knowledge, attitude and practice toward GERD were assessed using a questionnaire. Results: In our study of 411 participants, 92.5% knew about GERD. Correctly identified risk factors were smoking (62.3%), fatty food (84.2%), spicy food (91.2%) and meal timing (80.8%). Identified symptoms were burning sensation (92.2%) and regurgitation (81.0%). 43.6% of participants were unaware of GERD's complications. Only 46.2% would seek medical advice for feeling full after eating, but 85% would for severe symptoms. 88.7 and 86.8% of participants showed willingness to amend diet and lifestyle. Conclusion: General population has knowledge regarding GERD and its risk factors but poor attitude and practices toward the condition.
{"title":"Analysis of attitudes and practices toward gastroesophageal reflux disease among the general population of Pakistan.","authors":"Humaira Jabbar, Tooba Noor, Muhammad A Obaid, Areej Shakil, Muhammad I Obaid, Syeda I Aaqil, Usama Aa Memon, Zoha Mohsin","doi":"10.2144/fsoa-2023-0144","DOIUrl":"10.2144/fsoa-2023-0144","url":null,"abstract":"<p><p><b>Aim:</b> Gastro-esophageal reflux disease (GERD) is a growing health concern. <b>Methods:</b> In this cross-sectional study, participants' knowledge, attitude and practice toward GERD were assessed using a questionnaire. <b>Results:</b> In our study of 411 participants, 92.5% knew about GERD. Correctly identified risk factors were smoking (62.3%), fatty food (84.2%), spicy food (91.2%) and meal timing (80.8%). Identified symptoms were burning sensation (92.2%) and regurgitation (81.0%). 43.6% of participants were unaware of GERD's complications. Only 46.2% would seek medical advice for feeling full after eating, but 85% would for severe symptoms. 88.7 and 86.8% of participants showed willingness to amend diet and lifestyle. <b>Conclusion:</b> General population has knowledge regarding GERD and its risk factors but poor attitude and practices toward the condition.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2359843"},"PeriodicalIF":2.5,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}